Pasithea Therapeutics Corp.

NasdaqCM:KTTA Stock Report

Market Cap: US$17.4m

Pasithea Therapeutics Management

Management criteria checks 2/4

Pasithea Therapeutics' CEO is Tiago Marques, appointed in Aug 2020, has a tenure of 5.92 years. total yearly compensation is $1.33M, comprised of 40.2% salary and 59.8% bonuses, including company stock and options. directly owns 0.22% of the company’s shares, worth $38.13K. The average tenure of the management team and the board of directors is 3.8 years and 4.8 years respectively.

Key information

Tiago Marques

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage40.20%
CEO tenure5.9yrs
CEO ownership0.2%
Management average tenure3.8yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

Analysis Article • May 24

Is Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jul 21

We're Not Very Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Apr 06

Here's Why We're Not At All Concerned With Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

CEO Compensation Analysis

How has Tiago Marques's remuneration changed compared to Pasithea Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$20m

Dec 31 2025US$1mUS$534k

-US$20m

Sep 30 2025n/an/a

-US$13m

Jun 30 2025n/an/a

-US$13m

Mar 31 2025n/an/a

-US$14m

Dec 31 2024US$640kUS$450k

-US$14m

Sep 30 2024n/an/a

-US$16m

Jun 30 2024n/an/a

-US$16m

Mar 31 2024n/an/a

-US$16m

Dec 31 2023US$537kUS$450k

-US$16m

Sep 30 2023n/an/a

-US$15m

Jun 30 2023n/an/a

-US$15m

Mar 31 2023n/an/a

-US$14m

Dec 31 2022US$539kUS$450k

-US$12m

Sep 30 2022n/an/a

-US$7m

Jun 30 2022n/an/a

-US$4m

Mar 31 2022n/an/a

-US$3m

Dec 31 2021US$672kUS$244k

-US$2m

Compensation vs Market: Tiago's total compensation ($USD1.33M) is above average for companies of similar size in the US market ($USD658.93K).

Compensation vs Earnings: Tiago's compensation has increased whilst the company is unprofitable.

CEO

Tiago Marques (48 yo)

5.9yrs
Tenure
US$1,327,518
Compensation

Dr. Tiago Reis Marques, M. D., Ph. D., has been the Chief Executive Officer and Director at Pasithea Therapeutics Corp. since August 2020. He is a senior clinical fellow at Imperial College London and a le...

Leadership Team

NamePositionTenureCompensationOwnership
Lawrence Steinman
Co-Founder & Executive Chairman5.9yrsUS$345.27k0.60%
$ 103.8k
Tiago Marques
CEO & Director5.9yrsUS$1.33m0.22%
$ 38.1k
Daniel Schneiderman
Chief Financial Officer3.8yrsUS$895.19k0.080%
$ 13.9k
Kartik Krishnan
Chief Medical Officerless than a yearno datano data
3.8yrs
Average Tenure
48yo
Average Age

Experienced Management: KTTA's management team is considered experienced (3.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Lawrence Steinman
Co-Founder & Executive Chairman5.9yrsUS$345.27k0.60%
$ 103.8k
Tiago Marques
CEO & Director5.9yrsUS$1.33m0.22%
$ 38.1k
Alfred Novak
Independent Director3.8yrsUS$104.12k0.010%
$ 1.8k
Emer Leahy
Independent Director5.1yrsUS$84.12k0.10%
$ 17.3k
Daniel Weinberger
Member of Scientific Advisory Board4.4yrsno datano data
Luca Rastelli
Member of Scientific Advisory Boardno datano datano data
Simon Dumesnil
Independent Director5.3yrsUS$89.12k0.11%
$ 18.6k
James Lee
Member of Scientific Advisory Board1.1yrsno datano data
Rebecca Brown
Member of Scientific Advisory Board1.8yrsno datano data
4.8yrs
Average Tenure
58.5yo
Average Age

Experienced Board: KTTA's board of directors are considered experienced (4.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/07 00:43
End of Day Share Price 2026/07/07 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pasithea Therapeutics Corp. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sara NikH.C. Wainwright & Co.